- Latest Stories
- Commentary and Analysis
10:13AM ET 5/05/2023 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
11:04AM ET 3/03/2023 MT NewswiresAlector (ALEC) has an average outperform rating and a price target range of $6 to $41, according to analysts polled by Capital IQ. (MT Newswires covers...
10:59AM ET 3/02/2023 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
10:20AM ET 3/02/2023 MT NewswiresAlector (ALEC) has an average rating of outperform and price targets ranging from $6 to $41, according to analysts polled by Capital IQ. (MT Newswires...
10:45AM ET 3/01/2023 MT NewswiresAlector (ALEC) has an average outperform rating and price target range of $6 to $54, according to analysts polled by Capital IQ. (MT Newswires covers...
8:33AM ET 1/24/2023 MT NewswiresAlector (ALEC) has an average rating of outperform and price targets ranging from $6 to $54, according to analysts polled by Capital IQ. (MT Newswires...
1:41PM ET 11/29/2022 MT NewswiresAlector (ALEC) said Tuesday that its first-in-human phase 1 study of AL101 for the potential treatment of neurodegenerative diseases, including Alzheimer's...
10:02AM ET 11/10/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
8:09AM ET 9/12/2022 MT NewswiresAlector (ALEC) said Monday that it has initiated the first-in-human phase 1 trial of AL044 to treat Alzheimer's Disease. The study is intended to...
1:49PM ET 9/09/2022 MT NewswiresAlector (ALEC) shares fell nearly 10.5% in Friday afternoon trading after Morgan Stanley downgraded the stock to equalweight from overweight and cut the...